This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
MONARCH 3 was a randomized, double-blind, parallel-group phase 3 trial evaluating abemaciclib combined with a nonsteroidal aromatase inhibitor (NSAI) versus placebo combined with an NSAI in postmenopausal women with breast cancer. The registry reports 493 participants, two arms, and a primary time-to-event endpoint of progression-free survival.
| Feature | MONARCH 3 |
|---|---|
| Phase | Phase 3 |
| Condition | Breast Cancer |
| Brief title | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer |
| Design | Randomized, double-blind, parallel-group |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Enrollment | 493 |
| Primary endpoint | Progression Free Survival (PFS) |
| Primary endpoint type | Time-to-event |
| Hypothesis type | Superiority |
| Results posted | Yes |
| Statistical analyses posted | 6 |
| ClinicalTrials.gov | NCT02246621 |
2. Clinical Question
The central statistical question was whether adding abemaciclib to a nonsteroidal aromatase inhibitor improved progression-free survival compared with an NSAI regimen without abemaciclib in postmenopausal women with breast cancer.
Population
Postmenopausal women with breast cancer, as specified by the trial's registered brief title.
Intervention
Abemaciclib combined with a nonsteroidal aromatase inhibitor. The registered interventions include abemaciclib, anastrozole, and letrozole.
Comparator
Placebo combined with a nonsteroidal aromatase inhibitor. Placebo is listed as a registered intervention.
Primary question
Does abemaciclib plus an NSAI improve progression-free survival relative to placebo plus an NSAI?
3. Trial Design
Abemaciclib + NSAI
- Abemaciclib
- Nonsteroidal aromatase inhibitor
- Registered NSAI interventions include anastrozole and letrozole
Placebo + NSAI
- Placebo
- Nonsteroidal aromatase inhibitor
- Registered NSAI interventions include anastrozole and letrozole
The registry lists the study start as 2014-11-06 and the primary completion date as 2017-01-31. The current registry status in the ClinicalTrials.gov record is ACTIVE_NOT_RECRUITING.
4. Endpoints
The registry identifies one registered primary endpoint. Results were posted for that endpoint, and the registry contains six statistical analyses overall: one primary-endpoint analysis and five secondary analyses.
| Endpoint | Time frame | Type | Analysis reported |
|---|---|---|---|
| Progression Free Survival (PFS) | Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months) | Time-to-event | Log-rank test; hazard ratio |
| Change From Baseline to End of Study in Health Status on the EuroQuol 5-Dimension 5 Level (EuroQol-5D 5L) Index Value | Baseline, End of Study (Up to 32 Months) | Continuous | Mixed-effects model; mean difference |
| Change From Baseline to End of Study in Health Status on the EuroQol-5D 5L Visual Analog Scale (VAS) Scores Scale | Baseline, End of Study (Up to 32 Months) | Continuous | Mixed-effects model; mean difference |
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months) | Binary | Cochran-Mantel-Haenszel test |
| Percentage of Participants With CR, PR or Stable Disease (SD) (Disease Control Rate [DCR]) | Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months) | Binary | Cochran-Mantel-Haenszel test |
| Percentage of Participants With Tumor Response of SD for at Least 6 Months, PR, or CR (Clinical Benefit Rate [CBR]) | Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months) | Binary | Cochran-Mantel-Haenszel test |
Registered PFS definition
The registry defines PFS as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or the additional registry wording in the ClinicalTrials.gov record.
5. Statistical Methodology
Log-rank test for progression-free survival
The registered primary analysis uses the log-rank test to compare PFS between the abemaciclib + NSAI and placebo + NSAI groups. The analysis population is described as all randomized participants who had evaluable data.
The log-rank procedure compares the observed pattern of events between randomized groups over follow-up while accounting for the timing of events and censoring. The registry separately reports a hazard ratio as the effect measure.
Hazard ratio
The PFS effect measure is a hazard ratio. The posted estimate is 0.54, with a two-sided 95% confidence interval of 0.418 to 0.698.
Equivalently, 1 − 0.54 = 0.46, so the estimated hazard is 46% lower in the abemaciclib + NSAI group under the hazard-ratio interpretation. This is a relative time-to-event measure, not a statement that 46% of participants avoided progression or death.
Mixed-effects model for health-status outcomes
The two EuroQol outcomes were analyzed using a mixed-effects model. This is appropriate conceptually for repeated or longitudinal measurements because observations from the same participant are correlated rather than statistically independent.
A mixed-effects framework can represent both population-level effects and within-participant correlation. In MONARCH 3, the registry reports the resulting effect as a mean difference (net).
Cochran-Mantel-Haenszel test for binary outcomes
ORR, DCR, and CBR were analyzed using the Cochran-Mantel-Haenszel test. This is a family of methods for comparing categorical outcomes while allowing analysis across strata when the analysis specifies them. The ClinicalTrials.gov record does not identify the particular stratification variables used for these analyses.
Effect measures used in the registry analyses
| Endpoint type | Reported method | Reported effect measure |
|---|---|---|
| Time-to-event | Log-rank test | Hazard ratio |
| Continuous health-status outcome | Mixed-effects model | Mean difference (net) |
| Binary response outcome | Cochran-Mantel-Haenszel test | Registry reports P-value; no estimate is reported in the posted analysis |
6. Primary Result: Progression-Free Survival
The registry reports a formal statistical analysis for the primary endpoint of PFS. The comparison was between abemaciclib + NSAI and placebo + NSAI, using a log-rank test and a hazard ratio as the effect measure.
Progression-free survival
95% CI: 0.418–0.698 · P = 0.000002
Two-sided confidence interval and superiority hypothesis.
| Primary PFS analysis feature | Reported result |
|---|---|
| Endpoint | Progression Free Survival (PFS) |
| Time frame | Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months) |
| Analysis population | All randomized participants who had evaluable data |
| Censored participants | Abemaciclib + NSAI = 190; Placebo + NSAI = 57 |
| Comparison | Abemaciclib + NSAI vs Placebo + NSAI |
| Method | Log-rank test |
| Effect measure | Hazard ratio |
| Estimate | 0.54 |
| 95% CI | 0.418–0.698 |
| P-value | 0.000002 |
| Hypothesis | Superiority |
The hazard ratio of 0.54 means that the estimated instantaneous rate of progression or death was 54% of the corresponding rate in the placebo + NSAI group, under the hazard-ratio interpretation. Expressed as a relative reduction, 1 − 0.54 = 0.46, corresponding to a 46% lower estimated hazard.
The HR does not mean that 46% of participants were protected from progression, that every participant experienced the same reduction, or that the median PFS was reduced or increased by 46%. It is a relative time-to-event measure.
The 95% confidence interval of 0.418 to 0.698 describes uncertainty around the estimated hazard ratio under the statistical framework. Because the interval lies below 1, the posted interval is consistent with a lower estimated hazard in the abemaciclib + NSAI group.
The P = 0.000002 value addresses evidence against the null hypothesis used for the log-rank comparison. It does not measure the size of the treatment effect, does not give the probability that the treatment is effective, and does not describe the probability that the observed hazard ratio will recur in another study.
The analysis also includes censoring: 190 participants in the abemaciclib + NSAI group and 57 in the placebo + NSAI group were reported as censored. Consequently, PFS analysis is not equivalent to simply counting how many participants progressed. Interpretation depends on the timing of events and censoring.
7. Secondary Results
The registry contains five secondary statistical analyses. These analyses address health status, objective response, disease control, and clinical benefit. Unlike the primary PFS analysis, the ClinicalTrials.gov record does not provide effect estimates and confidence intervals for the three binary response endpoints.
Health status: EuroQol-5D 5L Index Value
Net mean difference
Two-sided P = 0.688
Mixed-effects model; outcome measured in units on a scale.
The endpoint was change from baseline to end of study in health status on the EuroQol-5D 5L Index Value, with assessment at baseline and end of study up to 32 months. The analysis population was all randomized participants.
The reported net mean difference was -0.01. The negative sign indicates the direction of the estimated between-group difference as defined by the registry's analysis, but the ClinicalTrials.gov record does not provide the underlying group-specific means needed to interpret the absolute change in each arm.
The P = 0.688 value is not a measure of the magnitude or clinical importance of the difference. It is a test statistic result under the specified superiority framework. The ClinicalTrials.gov record does not provide a confidence interval for this analysis.
Health status: EuroQol-5D 5L VAS
Net mean difference
Two-sided P = 0.466
Mixed-effects model; outcome measured in millimeters.
The endpoint measured change from baseline to end of study in the EuroQol-5D 5L Visual Analog Scale (VAS) Scores Scale, at baseline and end of study up to 32 months. All randomized participants were included in the stated analysis population.
The reported net mean difference was -1.01 mm. The ClinicalTrials.gov record identifies the direction and size of the estimated between-group difference but does not provide the arm-specific means or a confidence interval.
The P = 0.466 result should not be interpreted as evidence that the two treatments are identical. A nonsignificant P-value means that the analysis did not provide strong statistical evidence against its null hypothesis; it does not establish equivalence.
Objective Response Rate
Cochran-Mantel-Haenszel analysis
Superiority hypothesis; all randomized participants.
ORR was defined as the percentage of participants with complete response or partial response. The time frame was randomization to progressive disease or death due to any cause, up to 32 months. The reported method was the Cochran-Mantel-Haenszel test.
Disease Control Rate
Cochran-Mantel-Haenszel analysis
Superiority hypothesis; all randomized participants.
DCR was defined as the percentage of participants with complete response, partial response, or stable disease. The analysis covered randomization to progressive disease or death due to any cause, up to 32 months. The registry reports a Cochran-Mantel-Haenszel analysis with P = 0.501.
The ClinicalTrials.gov record does not report the arm-specific DCR percentages or an effect estimate and confidence interval. The P-value therefore should not be converted into an estimated treatment difference.
Clinical Benefit Rate
Cochran-Mantel-Haenszel analysis
Superiority hypothesis; all randomized participants.
CBR was defined as the percentage of participants with tumor response of stable disease for at least 6 months, partial response, or complete response. The time frame was randomization to progressive disease or death due to any cause, up to 32 months.
The reported Cochran-Mantel-Haenszel P-value was 0.101. No arm-specific percentage, effect estimate, or confidence interval is reported in the ClinicalTrials.gov record.
8. Safety Results
The ClinicalTrials.gov record provides serious adverse events by randomized treatment arm as affected participants divided by participants at risk. These figures are reported separately from the efficacy analyses.
| Safety measure | Abemaciclib + NSAI | Placebo + NSAI |
|---|---|---|
| Serious adverse events, affected / at risk | 102 / 327 | 27 / 161 |
The affected/at-risk figures correspond to approximately 31.2% and 16.8%, respectively, when calculated directly from the reported counts. These percentages are displayed only as a simple arithmetic representation of the registry-reported fractions; the underlying registry values remain 102/327 and 27/161.
9. Statistical Methods Explained
Why was a log-rank test used for PFS?
PFS is a time-to-event endpoint because both the timing of progression or death and the presence of censoring matter. A log-rank test compares the event-time experience of two groups across follow-up rather than reducing the outcome to a single binary status at one arbitrary date.
In MONARCH 3, the registry specifically reports the log-rank test for the primary PFS comparison. The corresponding effect measure is the hazard ratio.
What does a hazard ratio of 0.54 mean?
A hazard ratio of 0.54 means that the estimated instantaneous event rate in the abemaciclib + NSAI group was 0.54 times the corresponding rate in the placebo + NSAI group under the fitted time-to-event interpretation. This corresponds to an estimated 46% lower hazard.
It does not mean that 46% of participants avoided progression or death. It also does not mean that each individual experienced the same 46% reduction.
Why does the confidence interval matter?
The point estimate alone does not communicate statistical uncertainty. The 95% confidence interval of 0.418 to 0.698 shows the range of hazard-ratio values compatible with the specified confidence framework and observed data, subject to the assumptions of the analysis.
Because the entire reported interval is below 1, the interval is consistent with a lower estimated hazard for the abemaciclib + NSAI group.
Why does the P-value not measure effect size?
The P-value answers a hypothesis-testing question: how compatible are the observed data with the null hypothesis under the specified test? It does not quantify how large the treatment effect is. For MONARCH 3, the effect size is communicated by the hazard ratio and its confidence interval, while the P-value provides evidence concerning the statistical test.
Why use a mixed-effects model for the EuroQol outcomes?
The EuroQol outcomes are continuous measurements obtained at baseline and end of study. Measurements from the same participant are related, so treating every observation as independent can misrepresent uncertainty. A mixed-effects model provides a framework for modeling population-level treatment effects while accounting for participant-level variation and within-participant dependence.
What does the Cochran-Mantel-Haenszel test add to response analyses?
The Cochran-Mantel-Haenszel framework is designed for categorical comparisons and can account for stratification when strata are part of the analysis. In MONARCH 3, the registry identifies this method for ORR, DCR, and CBR. The ClinicalTrials.gov record does not specify the strata used for those analyses, so the page does not infer them.
Why should the secondary P-values not be treated as effect estimates?
A P-value such as 0.005 for ORR indicates the result of the reported statistical test, but it does not reveal the difference in response percentages. Without the arm-specific percentages or an effect estimate and confidence interval, the magnitude of the ORR difference cannot be reconstructed from the P-value alone.
10. Understanding Censoring in the PFS Analysis
The registry identifies 190 censored participants in the abemaciclib + NSAI group and 57 censored participants in the placebo + NSAI group within the primary analysis population.
What censoring means
A censored participant contributes information to the analysis up to the point at which their event status is no longer observed within the relevant follow-up framework.
What censoring does not mean
Censoring does not mean that a participant experienced progression at the censoring date. It means that the event time was not observed in the way required for an uncensored event.
Because PFS incorporates censoring, the analysis cannot be reproduced by simply dividing the number of participants who progressed by the total number randomized. The timing of events and follow-up contributes directly to the time-to-event comparison.
A time-to-event analysis asks about the distribution of the event time T. Kaplan-Meier estimation is commonly used to describe this distribution, while the log-rank test compares groups and a hazard ratio summarizes relative event rates under its modeling interpretation.
11. Primary Analysis Population
The posted PFS analysis population is described as all randomized participants who had evaluable data. The registry separately reports the number of censored participants in each treatment group.
| Analysis | Population reported in the trial data |
|---|---|
| Primary PFS | All randomized participants who had evaluable data |
| EuroQol Index Value | All randomized participants |
| EuroQol VAS | All randomized participants |
| ORR | All randomized participants |
| DCR | All randomized participants |
| CBR | All randomized participants |
The consistency of the stated randomized analysis populations for the secondary endpoints is important because randomized comparisons are intended to preserve the balance created by randomization. The ClinicalTrials.gov record does not provide additional analysis-population definitions beyond those listed above.
12. Statistical Interpretation of the Secondary Endpoints
| Endpoint | Estimate | P-value | Interpretive point |
|---|---|---|---|
| EuroQol-5D 5L Index Value | -0.01 mean difference | 0.688 | Direction and magnitude of the reported net mean difference; no CI reported. |
| EuroQol-5D 5L VAS | -1.01 mm mean difference | 0.466 | Reported net mean difference; no CI reported. |
| ORR | Not reported | 0.005 | CMH test result; arm-specific response percentages are not reported. |
| DCR | Not reported | 0.501 | CMH test result; arm-specific disease-control percentages are not reported. |
| CBR | Not reported | 0.101 | CMH test result; arm-specific clinical-benefit percentages are not reported. |
This distinction illustrates an important statistical reporting principle: an analysis result should not be made more precise than the source data permit. The P-values can be reported exactly as reported in the registry, but they cannot be used to derive missing response rates or confidence intervals.
13. What the PFS Hazard Ratio Does — and Does Not — Mean
The PFS hazard ratio of 0.54 indicates a lower estimated hazard of progression or death in the abemaciclib + NSAI group relative to placebo + NSAI. On the hazard-ratio scale, the estimate corresponds to a 46% lower estimated hazard.
A hazard ratio is not the same as an absolute reduction in the probability of progression or death. Absolute effects depend on the underlying event risk and follow-up time. The ClinicalTrials.gov record does not provide time-specific PFS probabilities or median PFS, so those quantities are not reported here.
The P-value of 0.000002 is not the probability that abemaciclib works, and the hazard ratio is not the proportion of participants who benefit. These quantities answer different statistical questions.
The 95% confidence interval of 0.418 to 0.698 provides the principal uncertainty statement posted on ClinicalTrials.gov for the primary PFS effect estimate. It is narrower than the full range of possible hazard ratios below and above 1 would have been, because the observed data provide information about the treatment comparison.
14. Limitations
- Registry-level reporting: this analysis is constrained to the ClinicalTrials.gov record. Where the registry does not provide a statistic, the page does not reconstruct it from external publications.
- Incomplete effect reporting for secondary endpoints: the analyses posted on ClinicalTrials.gov provide P-values for ORR, DCR, and CBR but not arm-specific percentages, effect estimates, or confidence intervals.
- No median PFS reported: the registry data identify the primary endpoint as a time-to-event outcome and provide a hazard ratio, but no median PFS is reported in the ClinicalTrials.gov record.
- Censoring: the primary PFS analysis contains censored participants, so interpretation depends on the timing of observed events and censoring rather than a simple event proportion.
- Hazard-ratio interpretation: a single hazard ratio summarizes relative event rates but should not be interpreted as an absolute risk difference or as a guarantee of a particular effect for every individual.
- Secondary endpoint precision: the absence of reported confidence intervals for the secondary analyses limits the ability to describe uncertainty around their estimated effects.
- Safety denominators: serious adverse events are reported using affected/at-risk counts of 102/327 and 27/161. These denominators differ from the overall enrollment of 493 and should not be substituted for it.
- Unreported design details: the ClinicalTrials.gov record does not report a non-inferiority margin, crossover scheme, factorial structure, interim-analysis plan, missing-data imputation strategy, stratification factors, or Bayesian methods. Those topics are therefore not inferred here.
15. Why This Trial Matters Statistically
MONARCH 3 is a useful teaching case because its registered analyses illustrate several distinct statistical problems within the same randomized trial: time-to-event analysis for PFS, longitudinal modeling for health-status outcomes, and categorical testing for response endpoints.
| Concept | How it appears in MONARCH 3 |
|---|---|
| Randomization | Participants were randomized in a two-arm parallel design. |
| Blinding | The registry describes the study as double-blind. |
| Time-to-event endpoint | PFS is defined from randomization to progressive disease or death due to any cause, up to 32 months. |
| Log-rank test | Used for the posted primary PFS comparison. |
| Hazard ratio | Used to quantify the primary PFS treatment effect. |
| Confidence interval | The PFS HR is accompanied by a two-sided 95% CI of 0.418–0.698. |
| Censoring | 190 and 57 censored participants are reported in the two PFS analysis groups. |
| Mixed-effects model | Used for changes in EuroQol-5D 5L Index Value and VAS. |
| Cochran-Mantel-Haenszel test | Used for ORR, DCR, and CBR. |
| P-values | Reported for all six posted statistical analyses. |
| Safety analysis | Serious adverse events are reported by arm using affected/at-risk counts. |
16. A Practical Statistical Reading of MONARCH 3
A useful way to read the trial is to move from the endpoint definition to the analysis method and only then to the numerical result.
Step 1: Identify the endpoint
PFS is a time-to-event endpoint, so the timing of progression, death, and censoring matters.
Step 2: Identify the test
The registry reports a log-rank test for the primary PFS comparison.
Step 3: Identify the effect measure
The effect is summarized by a hazard ratio rather than a simple difference in percentages.
Step 4: Read uncertainty
The HR of 0.54 is accompanied by a two-sided 95% CI from 0.418 to 0.698.
Step 5: Read the P-value separately
The P-value of 0.000002 describes evidence under the statistical test; it is not an effect-size measure.
Step 6: Check the analysis population
The primary analysis includes randomized participants with evaluable data, with censoring reported separately by group.
This sequence prevents a common interpretive error: treating a small P-value as if it were itself evidence about the magnitude or clinical importance of an effect. The numerical effect, its uncertainty, the analysis population, and the endpoint definition all contribute to the statistical interpretation.
17. Trial Timeline
Study start
The registry lists 2014-11-06 as the study start date.
Primary completion
The registry lists 2017-01-31 as the primary completion date.
Statistical results available
The ClinicalTrials.gov record indicates that results are posted, with 13 outcome measures and 6 statistical analyses.
Active, not recruiting
The ClinicalTrials.gov status is ACTIVE_NOT_RECRUITING.
18. Related Tutorials
Learn more about the methods used in this trial:
19. Related Calculators
20. Sources
- ClinicalTrials.gov: MONARCH 3, NCT02246621.
- PubMed: PMID 28968163.
- PubMed: PMID 30675515.
- PubMed: PMID 38470447.
- PubMed: PMID 36861085.
- PubMed: PMID 34661821.
Continue through the Clinical Biostats statistical pathway
Use the related tutorials and calculators to explore the time-to-event, categorical, longitudinal, and inference methods represented in MONARCH 3.
21. Record Summary
MONARCH 3 provides a compact example of how different clinical-trial endpoints require different statistical tools. The primary endpoint, PFS, is a time-to-event outcome analyzed with a log-rank test and summarized using a hazard ratio of 0.54 with a two-sided 95% confidence interval of 0.418–0.698 and P = 0.000002. The same trial also uses mixed-effects models for longitudinal health-status outcomes and Cochran-Mantel-Haenszel tests for binary response outcomes.
The most important statistical lesson is that these quantities should be interpreted according to what they actually measure. The hazard ratio describes a relative time-to-event effect; the confidence interval describes uncertainty around that estimate; the P-value describes evidence under a hypothesis test; and the secondary mean differences and categorical P-values address different outcome structures. Treating these quantities as interchangeable would obscure the statistical story of the trial.